Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Debt to Equity: 2017-2021

Historic Debt to Equity for Sunshine Biopharma (SBFM) over the last 3 years, with Dec 2021 value amounting to $8.98.

  • Sunshine Biopharma's Debt to Equity rose 1003.17% to $8.98 in Q4 2021 from the same period last year, while for Dec 2021 it was $34.23, marking a year-over-year increase of 3544.19%. This contributed to the annual value of $8.98 for FY2021, which is 1003.17% up from last year.
  • As of Q4 2021, Sunshine Biopharma's Debt to Equity stood at $8.98, which was up 428.88% from -$2.73 recorded in Q3 2021.
  • In the past 5 years, Sunshine Biopharma's Debt to Equity ranged from a high of $8.98 in Q4 2021 and a low of -$5.57 during Q4 2018.
  • Moreover, its 3-year median value for Debt to Equity was -$0.99 (2020), whereas its average is -$0.09.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 3,908.81% in 2018, then spiked by 1,003.17% in 2021.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Debt to Equity stood at -$0.14 in 2017, then slumped by 3,908.81% to -$5.57 in 2018, then crashed by 100.53% to -$0.04 in 2019, then slumped by 203.18% to -$0.99 in 2020, then surged by 1,003.17% to $8.98 in 2021.
  • Its last three reported values are $8.98 in Q4 2021, -$2.73 for Q3 2021, and -$2.35 during Q2 2021.